¶ National Institute of Allergy and Infectious Diseases
.png)
The National Institute of Allergy and Infectious Diseases (NIAID) is an agency of the United States Federal Government, one of the 27 institutes and centers that make up the National Institutes of Health (NIH).
¶ History
In December 2010, NIAID launched the Decade of Vaccines Collaboration alongside the Bill & Melinda Gates Foundation, UNICEF and the World Health Organization.[1]
On October 28, 2011, Robert Malone participated as a public commenter in a National Biodefense Science Board meeting in which he requested that NIAID invest in "dose pairing" studies for an anthrax vaccine under consideration. Other commenters included Meryl Nass and Vera Sherav, both of whom opposed pediatric studies due to known serious adverse events caused by the vaccine candidate.[2]
¶ COVID-19
At least two NIAID employees participated in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, including Clint Florence and Judith Hewitt.[3] NIAID is a partner organization of the National COVID Cohort Collaborative (N3C).[4]
NIAID funded the Adaptive COVID-19 Treatment Trial (ACTT) investigating remdesivir for the treatment of COVID-19.[5]
¶ Vaccine development
NIAID holds patent rights to a modified version of the SARS-CoV-2 spike protein, which have been licensed for use in currently available COVID-19 vaccines including mRNA-1273 and BNT162b2.[6] The associated patents are:[7][8]
- Prefusion Coronavirus Spike Proteins and Their Use
- 62/972,886
- PCT/US2021/017709
- US Application 17/798,021
The inventors listed on these patents within NIAID are financial beneficiaries of their use, presenting a conflict of interest between NIAID and pharmaceutical companies including Moderna and Pfizer.[9]
In May 2022, NIAID licensed various COVID-19-related technologies to the World Health Organization's COVID-19 Technology Access Pool (C-TAP).[10][11]
¶ Organization
| Name | Position | Notes |
|---|---|---|
| Anthony Fauci | Director (1984-2022)[12] | - |
| Dean Follmann | Chief, Biostatistics Research Branch[13] | Center for Naval Analyses (CNA), National Heart, Lung and Blood Institute (NHLBI), American Statistical Association, Food and Drug Administration (FDA) |
| Lisa Barrett | Postdoctoral and clinical science training[14] | COVID-19 Therapeutics Task Force, Dalhousie University, Senescence Aging Infection & Immunity Lab (SAIL) |
¶ Subsidiaries
- Vaccine Research Center
¶ Affiliations
NIAID has provided notable funding to:
- AMR One Health Consortium[15]
- Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)[16]
- Coronavirus Immunotherapy Consortium (CoVIC)[17]
¶ Publications
NIAID Biodefense Research Agenda for CDC Category A Agents
¶ External links
Robert, M., Hasan, H., Moen, C., & Billet, C. (2010, December 2). Global Health Leaders Launch Decade of Vaccines Collaboration. World Health Organization. http://archive.today/2013.10.30-095609/http://www.who.int/immunization/newsroom/press/news_release_decade_vaccines/en/index.html ↩︎
National Biodefense Science Board. (2011). Public Teleconference. Administration for Strategic Preparedness and Response. https://web.archive.org/web/20230621184603/https://www.phe.gov/Preparedness/legal/boards/nbsb/meetings/Documents/102811trans.pdf ↩︎
Preclinical Working Group. (2022, March 8). National Institutes of Health (NIH). http://archive.today/2022.04.02-062343/https://www.nih.gov/research-training/medical-research-initiatives/activ/preclinical-working-group ↩︎
N3C - Projects. National COVID Cohort Collaborative. Retrieved June 2, 2024, from https://web.archive.org/web/20240602001129/https://covid.cd2h.org/projects/ ↩︎
Thiede, J. M., Gress, A. R., Libby, S. D., Ronayne, C. E., Matchett, W. E., Noren, B., Billings, J. L., Menachery, V. D., Langlois, R. A., Kline, S., & Bold, T. D. (2021). Immune profiling to determine early disease trajectories associated with coronavirus disease 2019 mortality rate: a substudy from the ACTT-1 Trial. Journal of Infectious Diseases, 223(8), 1339–1344. https://doi.org/10.1093/infdis/jiab035 ↩︎
Rizvi, Z. (2020, June 25). The NIH Vaccine. Public Citizen. http://archive.today/2021.01.01-104304/https://www.citizen.org/article/the-nih-vaccine/ ↩︎
Petrik, A. (2022, April 28). Prefusion Coronavirus Spike Proteins and Their Use. NIH Technology Transfer. https://web.archive.org/web/20230301012116/https://www.techtransfer.nih.gov/tech/tab-3532 ↩︎
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 367(6483), 1260–1263. https://doi.org/10.1126/science.abb2507 ↩︎
COVID-19 Vaccines: Dr. Fauci’s Team May Personally Profit. (2020, October 11). ICAN - Informed Consent Action Network. http://archive.today/2023.03.01-015445/https://icandecide.org/article/covid-19-vaccines-dr-faucis-team-may-personally-profit/ ↩︎
NIH Contributions to WHO COVID-19 Technology Access Pool and Q&As | Technology Transfer. (2022, May 12). National Institutes of Health. https://web.archive.org/web/20230301014813/https://www.techtransfer.nih.gov/policy/ctap ↩︎
US NIH licenses to C-TAP. World Health Organization. Retrieved March 1, 2023, from https://web.archive.org/web/20230301024934/https://www.who.int/initiatives/covid-19-technology-access-pool/us-nih-licenses ↩︎
Previous Directors. NIH: National Institute of Allergy and Infectious Diseases. Retrieved August 22, 2023, from https://web.archive.org/web/20230822173840/https://www.niaid.nih.gov/about/directors ↩︎
Dean Follmann, Ph.D. (2017, May 10). National Institute of Allergy and Infectious Diseases. http://archive.today/2023.12.01-053526/https://www.niaid.nih.gov/about/brb-staff-follmann ↩︎
Innovation, Science and Economic Development Canada. (2022, March 10). COVID-19 Therapeutics Task Force. Government of Canada. http://archive.today/2023.04.27-230206/https://ised-isde.canada.ca/site/canadian-life-science-industries/en/covid-19-therapeutics-task-force ↩︎
Funders. (2022). Research at UCalgary. http://archive.today/2022.06.07-225624/https://research.ucalgary.ca/amr/about-us/funders ↩︎
Funding Partners. (2022). CARB-X. http://archive.today/2022.06.06-075157/https://carb-x.org/partners/funding-partners/ ↩︎
About CoVIC. Coronavirus Immunotherapy Consortium. Retrieved January 19, 2023, from https://web.archive.org/web/20230119213917/https://covic.lji.org/about/ ↩︎